-transparent.png){kind=logo}
Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders. Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors. A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension. The patient was in near syncope and had QT-interval prolongation. After discontinuing cisapride, the QT interval returned to normal and symptoms did not recur. We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4, including diltiazem.
A R Thomas, and
L N Chan, and
J L Bauman, and
C O Olopade
January 1985,
The Journal of emergency medicine,
A R Thomas, and
L N Chan, and
J L Bauman, and
C O Olopade
January 1993,
European journal of clinical pharmacology,
A R Thomas, and
L N Chan, and
J L Bauman, and
C O Olopade
February 1996,
The Journal of pediatrics,
A R Thomas, and
L N Chan, and
J L Bauman, and
C O Olopade
January 2010,
Cardiology journal,
A R Thomas, and
L N Chan, and
J L Bauman, and
C O Olopade
January 1992,
Annals of the New York Academy of Sciences,
A R Thomas, and
L N Chan, and
J L Bauman, and
C O Olopade
July 1972,
British heart journal,
A R Thomas, and
L N Chan, and
J L Bauman, and
C O Olopade
March 2021,
Cureus,
A R Thomas, and
L N Chan, and
J L Bauman, and
C O Olopade
August 2011,
Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology,
A R Thomas, and
L N Chan, and
J L Bauman, and
C O Olopade
June 2003,
The British journal of psychiatry : the journal of mental science,
A R Thomas, and
L N Chan, and
J L Bauman, and
C O Olopade
February 1996,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
